{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:40:37Z","timestamp":1793500837358,"version":"4.5.0"},"reference-count":71,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamapsychiatry.2019.1427","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T11:32:04Z","timestamp":1562153524000},"page":"1074","source":"Crossref","is-referenced-by-count":70,"title":["In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis"],"prefix":"10.1001","volume":"76","author":[{"given":"Faith","family":"Borgan","sequence":"first","affiliation":[{"name":"Psychosis Studies Department, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Laurikainen","sequence":"additional","affiliation":[{"name":"Turku PET (Positron Emission Tomography) Centre, University of Turku and Turku University Hospital, Turku, Finland."},{"name":"Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[{"name":"Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Reis","family":"Marques","sequence":"additional","affiliation":[{"name":"Psychosis Studies Department, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Haaparanta-Solin","sequence":"additional","affiliation":[{"name":"Turku PET (Positron Emission Tomography) Centre, University of Turku and Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Solin","sequence":"additional","affiliation":[{"name":"Turku PET (Positron Emission Tomography) Centre, University of Turku and Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Dahoun","sequence":"additional","affiliation":[{"name":"MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"},{"name":"Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom"},{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rogdaki","sequence":"additional","affiliation":[{"name":"MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimo KR","family":"Salokangas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Karukivi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Turku University, Satakunta Hospital District, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Di Forti","sequence":"additional","affiliation":[{"name":"Psychosis Studies Department, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Turkheimer","sequence":"additional","affiliation":[{"name":"Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmo","family":"Hietala","sequence":"additional","affiliation":[{"name":"Turku PET (Positron Emission Tomography) Centre, University of Turku and Turku University Hospital, Turku, Finland."},{"name":"Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[{"name":"Psychosis Studies Department, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom"},{"name":"Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the METSY Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"yoi190037r1","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia.","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"issue":"9173","key":"yoi190037r2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0140-6736(98)07507-2","article-title":"Multiple-informant ranking of the disabling effects of different health conditions in 14 countries.","volume":"354","author":"Ust\u00fcn","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"yoi190037r3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis.","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr Bull"},{"issue":"4","key":"yoi190037r4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"yoi190037r5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/schbul\/sbu098","article-title":"How cannabis causes paranoia: using the intravenous administration of ?9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia.","volume":"41","author":"Freeman","year":"2015","journal-title":"Schizophr Bull"},{"issue":"10","key":"yoi190037r6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous ?9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol Med"},{"key":"yoi190037r7","article-title":"The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species","author":"Borgan","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"yoi190037r8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"4","key":"yoi190037r9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.","volume":"194","author":"Koethe","year":"2009","journal-title":"Br J Psychiatry"},{"issue":"11","key":"yoi190037r10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1-3","key":"yoi190037r11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"issue":"5","key":"yoi190037r12","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain.","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"yoi190037r13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"yoi190037r14","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder.","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"yoi190037r15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.","volume":"206","author":"Urig\u00fcen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"yoi190037r16","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"yoi190037r17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.","volume":"172","author":"Newell","year":"2006","journal-title":"Exp Brain Res"},{"issue":"2","key":"yoi190037r18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2-3","key":"yoi190037r19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr Res"},{"key":"yoi190037r20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia.","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"issue":"4","key":"yoi190037r21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"issue":"12","key":"yoi190037r22","first-page":"997","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia.","volume":"79","author":"Ranganathan","year":"2016"},{"issue":"5","key":"yoi190037r23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1109\/TBME.10","article-title":"A unified framework for plasma data modelling in dynamic positron emission tomography studies.","volume":"66","author":"Tonietto","year":"2018","journal-title":"IEEE Trans Biomed Eng"},{"key":"yoi190037r24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.neuroimage.2018.10.013","article-title":"Sex difference in brain CB1 receptor availability in man.","volume":"184","author":"Laurikainen","year":"2019","journal-title":"Neuroimage"},{"key":"yoi190037r25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.eurpsy.2017.12.001","article-title":"Platform for systems medicine research and diagnostic applications in psychotic disorders: the METSY project.","volume":"50","author":"Frank","year":"2018","journal-title":"Eur Psychiatry"},{"issue":"8","key":"yoi190037r27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","article-title":"Equipercentile linking of the BPRS and the PANSS.","volume":"23","author":"Leucht","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"yoi190037r29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"3","key":"yoi190037r30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"1","key":"yoi190037r31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/arclin\/acq086","article-title":"A digit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis.","volume":"26","author":"Gonz\u00e1lez-Blanch","year":"2011","journal-title":"Arch Clin Neuropsychol"},{"issue":"5","key":"yoi190037r32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.","volume":"10","author":"Logan","year":"1990","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"yoi190037r33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamapsychiatry.2017.2663","article-title":"Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis.","volume":"74","author":"Brugger","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"yoi190037r34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00702-007-0859-5","article-title":"Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review.","volume":"115","author":"Watis","year":"2008","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"yoi190037r35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2013.2437","article-title":"Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.","volume":"70","author":"Kraguljac","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"yoi190037r36","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis.","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr Bull"},{"issue":"1","key":"yoi190037r37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cercor\/bhj133","article-title":"Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons.","volume":"17","author":"Fortin","year":"2007","journal-title":"Cereb Cortex"},{"issue":"1","key":"yoi190037r38","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1038\/s41598-017-07519-8","article-title":"A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum.","volume":"7","author":"Musella","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"yoi190037r39","doi-asserted-by":"publisher","first-page":"e92224","DOI":"10.1371\/journal.pone.0092224","article-title":"Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.","volume":"9","author":"Dazzi","year":"2014","journal-title":"PLoS One"},{"issue":"6828","key":"yoi190037r40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/35069076","article-title":"Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.","volume":"410","author":"Wilson","year":"2001","journal-title":"Nature"},{"key":"yoi190037r41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuroscience.2014.01.049","article-title":"Anandamide activation of CB1 receptors increases spontaneous bursting and oscillatory activity in the thalamus.","volume":"265","author":"Dasilva","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"yoi190037r42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/(ISSN)1097-0193","article-title":"Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.","volume":"19","author":"Hammers","year":"2003","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"yoi190037r43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia.","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr Res"},{"issue":"7","key":"yoi190037r44","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.neuropharm.2008.07.026","article-title":"Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats.","volume":"55","author":"Wiley","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1-2","key":"yoi190037r45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0014-2999(00)00480-5","article-title":"A performance-dependent adjustment of the retention interval in a delayed non\u2013matching-to-position paradigm differentiates effects of amnestic drugs in rats.","volume":"403","author":"Han","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"yoi190037r46","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/0269881116652585","article-title":"Involvement of medial prefrontal cortex alpha-2 adrenoceptors on memory acquisition deficit induced by arachidonylcyclopropylamide, a cannabinoid CB1 receptor agonist, in rats; possible involvement of Ca2+ channels.","volume":"30","author":"Beiranvand","year":"2016","journal-title":"J Psychopharmacol"},{"key":"yoi190037r47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neuroscience.2015.12.010","article-title":"Synergistic effect between prelimbic 5-HT3 and CB1 receptors on memory consolidation deficit in adult male Sprague-Dawley rats: an isobologram analysis.","volume":"317","author":"Ahmadi-Mahmoodabadi","year":"2016","journal-title":"Neuroscience"},{"issue":"1","key":"yoi190037r48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2967\/jnumed.109.067074","article-title":"Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.","volume":"51","author":"Terry","year":"2010","journal-title":"J Nucl Med"},{"issue":"2","key":"yoi190037r49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.npp.1301402","article-title":"The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain.","volume":"33","author":"Yasuno","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"yoi190037r50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1046\/j.1471-4159.1999.0730493.x","article-title":"Internalization and recycling of the CB1 cannabinoid receptor.","volume":"73","author":"Hsieh","year":"1999","journal-title":"J Neurochem"},{"issue":"7","key":"yoi190037r51","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1523\/JNEUROSCI.21-07-02425.2001","article-title":"Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons.","volume":"21","author":"Coutts","year":"2001","journal-title":"J Neurosci"},{"issue":"8","key":"yoi190037r52","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/npp.2010.44","article-title":"FAAH-\/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.","volume":"35","author":"Falenski","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"yoi190037r53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/oxfordjournals.schbul.a007038","article-title":"The stress cascade and schizophrenia: etiology and onset.","volume":"29","author":"Corcoran","year":"2003","journal-title":"Schizophr Bull"},{"issue":"11","key":"yoi190037r54","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/npp.2012.100","article-title":"Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.","volume":"37","author":"Dlugos","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1-3","key":"yoi190037r55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2009.04.048","article-title":"Chronic stress differentially regulates cannabinoid CB1 receptor binding in distinct hippocampal subfields.","volume":"614","author":"Hill","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"9929","key":"yoi190037r56","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model.","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"yoi190037r57","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","article-title":"Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.","volume":"24","author":"Osimo","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"3","key":"yoi190037r58","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0896-6273(01)00372-5","article-title":"Presynaptic specificity of endocannabinoid signaling in the hippocampus.","volume":"31","author":"Wilson","year":"2001","journal-title":"Neuron"},{"issue":"23","key":"yoi190037r59","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.1523\/JNEUROSCI.0247-14.2014","article-title":"Presynaptic calcium channel inhibition underlies CB1 cannabinoid receptor-mediated suppression of GABA release.","volume":"34","author":"Szab\u00f3","year":"2014","journal-title":"J Neurosci"},{"issue":"7","key":"yoi190037r60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies.","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"yoi190037r61","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine function in first-episode psychosis: a multi-modal PET and magnetic resonance spectroscopy imaging study.","volume":"5","author":"Jauhar","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi190037r62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1523\/JNEUROSCI.4503-03.2004","article-title":"Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors.","volume":"24","author":"Melis","year":"2004","journal-title":"J Neurosci"},{"issue":"1-3","key":"yoi190037r63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0014-2999(03)01734-5","article-title":"Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes.","volume":"469","author":"Wang","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"yoi190037r64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1517\/14728210902736568","article-title":"Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"10","key":"yoi190037r65","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/sj.npp.1301344","article-title":"Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.","volume":"32","author":"Ballmaier","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yoi190037r66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies.","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"issue":"20","key":"yoi190037r67","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"8","key":"yoi190037r68","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2012.100","article-title":"Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.","volume":"18","author":"Hirvonen","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"5","key":"yoi190037r69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","article-title":"Digit Symbol Substitution Test: the case for sensitivity over specificity in neuropsychological testing.","volume":"38","author":"Jaeger","year":"2018","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi190037r70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/01.ftd.0000197091.07807.22","article-title":"Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use.","volume":"28","author":"Musshoff","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"1","key":"yoi190037r71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bpsc.2015.09.008","article-title":"Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis.","volume":"1","author":"D\u2019Souza","year":"2016","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"yoi190037r26","volume-title":"Structured Clinical Interview of DSM-IV-TR Axis I Disorders\u2013Patient Edition","author":"First","year":"2007"},{"key":"yoi190037r28","author":"Hunter","year":"2011"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2737034\/jamapsychiatry_borgan_2019_oi_190037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T11:00:52Z","timestamp":1570014052000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2737034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1427","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736126393.793565779","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736126393.793565586","asserted-by":"object"}]},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}